Comparison of Acute Toxicities and Locoregional Control of Intracavitary Brachytherapy With or Without Concurrent Weekly Cisplatin in Patients of Locally Advanced Cervical Carcinoma Following Concurrent Chemoradiation

ABSTRACT

Cervical cancer is one of the leading causes of cancer-related deaths in developing countries. Between 80% and 90% of cervical carcinomas are squamous cell carcinomas. Concurrent chemo radiation with Inj. Cisplatin given every week followed by intracavitary Brachytherapy has become the standard of treatment in locally advanced cervical carcinoma Methods: 60 biopsy proven cases of locally advanced cervical cancer attending the Out Patient Department of Radiotherapy from November 2017 to April 2019, meeting specified Inclusion and Exclusion Criteria, willing to participate in the study were included. Acute toxicities and locoregional control were assessed using the common terminology criteria for adverse events (CTCAE) version 4.0. During treatment patients will be reviewed weekly. After treatment completion, patients will be reviewed monthly for six months. And after that, they will be reviewed every 3 months for 9 months. Results: The median age was 50 years (range 40–60 years) in both the arms. On analysing the pattern of response, in Arm A the number of patients having complete response was 29 (96.66%), partial response was 1 (3.34%). In the Arm B all patients have complete response. The incidence of Emesis, Dermatitis, Neutropenia, and Vaginal Mucocytis were more in Arm B as compared to Arm A. Conclusion: In locally advanced squamous cell carcinoma of uterine cervix, addition of concurrent injection Cisplatin to ICRT did not significantly improve loco regional response but increases incidence of haematological and mucosal toxicity, which being manageable, were not associated with increased mortality.